Targeting group‐I PAKs (PAK1‐3) has also been demonstrated to suppress tumor growth and metastasis in prostate (Al‐Azayzih et al., 2016; Najahi‐Missaoui et al., 2020; Verma, Artham, et al., 2020; Verma, Najahi‐Missaoui, et al., 2020) and a variety of other cancer types (Kichina et al., 2010; Somanath et al., 2023). Here, PAK1 is linked to cancer.